In a recent high-throughput drug screening in AML 8227 cells, cardiac glycosides strophanthidin, ouabain, and digoxin in the micromolar range for 6 days were shown to be effective against all leukemic populations tested, including CD34+CD38− LSCs, CD34+CD38+ LPCs, and CD15+ mature myeloid cells [14]. The gene discussed is CD38; the disease is acute myeloid leukemia.